$59.63 Million in Sales Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter

Wall Street brokerages predict that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will post $59.63 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Halozyme Therapeutics’ earnings. The highest sales estimate is $65.89 million and the lowest is $55.35 million. Halozyme Therapeutics reported sales of $60.23 million in the same quarter last year, which indicates a negative year-over-year growth rate of 1%. The firm is expected to issue its next earnings results on Thursday, February 20th.

On average, analysts expect that Halozyme Therapeutics will report full year sales of $201.96 million for the current financial year, with estimates ranging from $197.68 million to $208.22 million. For the next financial year, analysts expect that the company will post sales of $203.71 million, with estimates ranging from $190.06 million to $221.44 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05). Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.76%. The firm had revenue of $46.20 million during the quarter, compared to analyst estimates of $54.96 million. During the same quarter in the previous year, the business posted ($0.19) EPS. Halozyme Therapeutics’s revenue was up 80.5% compared to the same quarter last year.

A number of research analysts recently weighed in on HALO shares. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a report on Thursday, November 7th. Barclays upgraded Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and reduced their target price for the company from $17.00 to $16.00 in a report on Tuesday, November 5th. BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, ValuEngine cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $20.50.

A number of institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY boosted its holdings in Halozyme Therapeutics by 14.9% in the third quarter. Metropolitan Life Insurance Co NY now owns 46,666 shares of the biopharmaceutical company’s stock valued at $724,000 after acquiring an additional 6,034 shares during the last quarter. Millennium Management LLC purchased a new position in Halozyme Therapeutics in the third quarter valued at about $4,888,000. Man Group plc raised its position in Halozyme Therapeutics by 22.7% in the third quarter. Man Group plc now owns 727,733 shares of the biopharmaceutical company’s stock valued at $11,287,000 after purchasing an additional 134,675 shares during the period. Zebra Capital Management LLC purchased a new position in Halozyme Therapeutics in the third quarter valued at about $211,000. Finally, California State Teachers Retirement System raised its position in Halozyme Therapeutics by 1.2% in the third quarter. California State Teachers Retirement System now owns 223,062 shares of the biopharmaceutical company’s stock valued at $3,460,000 after purchasing an additional 2,665 shares during the period. Hedge funds and other institutional investors own 84.98% of the company’s stock.

Halozyme Therapeutics stock traded up $0.26 during midday trading on Friday, reaching $18.98. The stock had a trading volume of 1,212,665 shares, compared to its average volume of 1,663,413. Halozyme Therapeutics has a twelve month low of $13.24 and a twelve month high of $19.73. The stock has a market capitalization of $2.74 billion, a PE ratio of -33.89 and a beta of 1.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.83 and a current ratio of 3.17. The stock’s 50-day simple moving average is $17.87 and its 200 day simple moving average is $16.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

See Also: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.